{"name":"ENNOGEN PHARMA LTD","company_number":"07751819","status":"Active","type":"Private Limited Company","incorporated":"2011-08-24","dissolved":null,"registered_office":"Unit G4 Riverside Industrial Estate, Riverside Way, Dartford, Kent, DA1 5BS","postcode":"DA1 5BS","sic_codes":[{"code":21100,"description":"Manufacture of basic pharmaceutical products"},{"code":46460,"description":"Wholesale of pharmaceutical goods"}],"principal_activity":null,"previous_names":[],"warnings":[],"accounts":{"category":"Total Exemption Full","year_end":"31 December","last_made_up_to":"2025-12-31","next_due":"2027-09-30"},"employees":{"count":2,"accounts_date":"2022-12-31"},"financials":[{"financial_date":"2022-12-31","profit_loss":603207,"net_assets":1598466,"cash":161755,"average_employees":2},{"financial_date":"2021-12-31","profit_loss":83161,"net_assets":995259,"cash":48653,"average_employees":4},{"financial_date":"2020-12-31","net_assets":912098,"cash":27802},{"financial_date":"2019-12-31","net_assets":632323,"cash":58465},{"financial_date":"2018-12-31","net_assets":575682,"cash":99644}],"officers":{"current":1,"resigned":0,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"Ennogen Pharma Ltd has undergone a remarkable financial transformation over the past decade, progressing from negative net assets in 2013-2014 to a £1.6M net asset position by 2022, with particularly strong profit growth in the most recent year (£603k vs £83k in 2021). However, this performance is substantially underpinned by intercompany trading — 78% of debtors are group undertakings — indicating the company functions primarily as a manufacturing or distribution hub within the wider Ennogen group rather than as a standalone market competitor. The pharmaceutical manufacturing and wholesale sector's structural advantages (defensive demand, generic medicines growth, post-Brexit reshoring) provide a favourable backdrop, but the company's minimal workforce of two employees, heavy intercompany dependency, and single-director governance structure present meaningful concentration and key-person risks that warrant ongoing monitoring.","website":"https://ennogen.com/","links":{"page":"https://www.companiesintheuk.co.uk/ltd/ennogen-pharma","people":"https://www.companiesintheuk.co.uk/company/ennogen-pharma/people","filing_history":"https://www.companiesintheuk.co.uk/company/ennogen-pharma/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/07751819","financials":"https://www.companiesintheuk.co.uk/company/ennogen-pharma/financial","control":"https://www.companiesintheuk.co.uk/company/ennogen-pharma/control","charges":"https://www.companiesintheuk.co.uk/company/ennogen-pharma/charges","ai_analysis":"https://www.companiesintheuk.co.uk/company/ennogen-pharma/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/ennogen-pharma"}